Abstract:Objective: Polycystic ovary syndrome (PCOS) is a condition of androgen excess and chronic anovulation frequently associated with insulin resistance. We combined a nontargeted and targeted metabolomics approach to identify pathways and metabolites that distinguished PCOS from metabolic syndrome (MetS). Methods: Twenty obese women with PCOS were compared with 18 obese women without PCOS. Both groups met criteria for MetS but could not have diabetes mellitus or take medications that treat PCOS or affect lipids or insulin sensitivity. Insulin sensitivity was derived from the frequently sampled intravenous glucose tolerance test. A nontargeted metabolomics approach was performed on fasting plasma samples to identify differentially expressed metabolites, which were further evaluated by principal component and pathway enrichment analysis. Quantitative targeted metabolomics was then applied on candidate metabolites. Measured metabolites were tested for associations with PCOS and clinical variables by logistic and linear regression analyses. Results: This multiethnic, obese sample was matched by age (PCOS, 37±6; MetS, 40±6years) and body mass index (BMI) (PCOS, 34.6±5.1; MetS, 33.7±5.2kg/m2). Principal component analysis of the nontargeted metabolomics data showed distinct group separation of PCOS from MetS controls. From the subset of 385 differentially expressed metabolites, 22% were identified by accurate mass, resulting in 19 canonical pathways significantly altered in PCOS, including amino acid, lipid, steroid, carbohydrate, and vitamin D metabolism. Targeted metabolomics identified many essential amino acids, including branched-chain amino acids (BCAA) that were elevated in PCOS compared with MetS. PCOS was most associated with BCAA (P=.02), essential amino acids (P=.03), the essential amino acid lysine (P=.02), and the lysine metabolite α-aminoadipic acid (P=.02) in models adjusted for surrogate variables representing technical variation in metabolites. No significant differences between groups were observed in concentrations of free fatty acids or vitamin D metabolites. Evaluation of the relationship of metabolites with clinical characteristics showed 1) negative associations of essential and BCAA with insulin sensitivity and sex hormone-binding globulin and 2) positive associations with homeostasis model of insulin resistance and free testosterone; metabolites were not associated with BMI or percent body fat. Conclusions: PCOS was associated with significant metabolic alterations not attributed exclusively to androgen-related pathways, obesity, or MetS. Concentrations of essential amino acids and BCAA are increased in PCOS, which might result from or contribute to their insulin resistance.

Serum metabolomics analysis of patients with polycystic ovary syndrome by mass spectrometry

Untargeted Metabolomics Analysis of Serum and Follicular Fluid Samples from Women with Polycystic Ovary Syndrome.

UHPLC/Q-TOFMS-based Plasma Metabolomics of Polycystic Ovary Syndrome Patients with and Without Insulin Resistance

Metabolic profiles characterizing different phenotypes of polycystic ovary syndrome: plasma metabolomics analysis

Non-invasive Urinary Metabolomics Reveals Metabolic Profiling of Polycystic Ovary Syndrome and Its Subtypes.

UPLC/Q‑TOF‑MS Based Plasma Metabolomics and Clinical Characteristics of Polycystic Ovarian Syndrome.

Metabolic alterations associated with polycystic ovary syndrome: A UPLC Q-Exactive based metabolomic study.

Serum metabolomic profiling reveals potential biomarkers in assessing the management of women with polycystic ovary syndrome: a randomized controlled trial

Urinary Metabolomics Identified Metabolic Disturbance Associated with Polycystic Ovary Syndrome.

Serum metabolomics reveals metabolic profiling for women with hyperandrogenism and insulin resistance in polycystic ovary syndrome

How to Screen and Prevent Metabolic Syndrome in Patients of PCOS Early: Implications From Metabolomics

Combining a nontargeted and targeted metabolomics approach to identify metabolic pathways significantly altered in polycystic ovary syndrome

Searching for the primary metabolic alterations of polycystic ovary syndrome by application of the untargeted metabolomics approach

Integrated lipid metabolomics and proteomics analysis reveal the pathogenesis of polycystic ovary syndrome

Metabolic Disorder and Polycystic Ovary Syndrome: Challenges and Opportunities

Serum metabolomics study of Traditional Chinese medicine formula intervention to polycystic ovary syndrome

Metabolomic Analysis of Follicular Fluid in Normal-Weight Patients with Polycystic Ovary Syndrome

Steroid metabolome profiling of follicular fluid in normo- and hyperandrogenic women with polycystic ovary syndrome

Metabolic Syndrome and PCOS: Pathogenesis and the Role of Metabolites

DIA proteomics analysis through serum profiles reveals the significant proteins as candidate biomarkers in women with PCOS

Serum Steroid Metabolome on the Day of Oocyte Retrieval in Women with Polycystic Ovarian Syndrome and Its Association with Pregnancy Outcome of in Vitro Fertilization.